List of Dassault Medidata Platform Customers
Velizy-Villacoublay, 78140,
France
Since 2010, our global team of researchers has been studying Dassault Medidata Platform customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Dassault Medidata Platform for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Dassault Medidata Platform for Clinical Trial Management include: Moderna, a United States based Life Sciences organisation with 5600 employees and revenues of $6.75 billion, University of Southampton, a United Kingdom based Education organisation with 6500 employees and revenues of $1.30 billion, ClinChoice, a United States based Life Sciences organisation with 4000 employees and revenues of $750.0 million, Catalyst Clinical Research, a United States based Professional Services organisation with 1000 employees and revenues of $200.0 million and many others.
Contact us if you need a completed and verified list of companies using Dassault Medidata Platform, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Dassault Medidata Platform customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Catalyst Clinical Research | Professional Services | 1000 | $200M | United States | Dassault Systemes | Dassault Medidata Platform | Clinical Trial Management | 2023 | n/a |
In 2023, Catalyst Clinical Research expanded deployment of the Dassault Medidata Platform for Clinical Trial Management to support its global oncology brand, Catalyst Oncology. This multi-year partnership expansion builds on Catalyst’s initial use of the Medidata Platform since 2019 and aligns explicitly with the organization’s portfolio that includes more than 80 active oncology trials across Phases I-III and a historical support footprint of over 150 oncology studies.
The deployment incorporates Medidata Rave EDC, Medidata Rave CTMS, Medidata Rave eTMF, Medidata Grants Manager, and Medidata AI Intelligent Trials as integrated components of the Dassault Medidata Platform. Configuration emphasis is on unified data capture and trial operations workflows, centralized electronic trial master file lifecycle management, automated grants administration, and AI enabled decision support, enabling streamlined workflows and automated document management across study phases.
Operationally the implementation targets trial operations, study start up, regulatory documentation control, and patient enrollment for Catalyst Oncology on a global basis. Medidata AI Intelligent Trials is being used with a dataset spanning more than 20 years to inform enrollment strategies and to engage a more diverse patient population, while the combined Rave EDC, Rave CTMS, and Rave eTMF capabilities provide end to end visibility to critical trial metrics.
Governance and rollout focus on centralized visibility and control of trial documentation and metrics, and on scaling platform capability to support Catalyst’s growth in complex oncology research. Reported outcomes include streamlined operational workflows, automated document management, improved visibility to trial metrics, and accelerated enrollment through AI, reflecting Catalyst’s recommitment to the core elements of the Dassault Medidata Platform for Clinical Trial Management.
|
 |
ClinChoice | Life Sciences | 4000 | $750M | United States | Dassault Systemes | Dassault Medidata Platform | Clinical Trial Management | 2024 | n/a |
In 2024 ClinChoice extended its 13 year partnership with Medidata by formalizing expanded use of the Dassault Medidata Platform as part of a renewed enterprise agreement. The decision centralizes Clinical Trial Management capabilities on the Dassault Medidata Platform to streamline study data and supply management across ClinChoice operations and to support the company as a full service CRO in Asia, Europe, and North America.
The implementation specifically adds Medidata Clinical Data Studio to ClinChoice’s existing Medidata footprint, building on prior use of Medidata Rave EDC that began in 2011 and earlier deployments of Rave RTSM for Direct to Patient inventory models. Clinical Data Studio is being prioritized for accreditation to deliver an AI powered data quality management experience, and the expanded platform use emphasizes automation, advanced analytics, and unified cloud data workflows for EDC, RTSM, and study supply orchestration.
Operational coverage is focused on securing connections among patients, sites, and sponsors within a unified cloud environment, while consolidating study data and supply chains to accommodate multi region regulatory requirements. The deployment supports clinical data management, clinical operations, and clinical supply planning functions, and it continues ClinChoice’s use of Medidata capabilities to optimize patient access and inventory across diverse regions.
Governance actions in the renewal include pursuing Clinical Data Studio accreditation and embedding standardized data quality processes and workflows to reduce complexity in study execution. ClinChoice states the outcome objectives are to boost trial efficiency, accelerate research, strengthen operational efficiency, and enable growth as a global CRO, all delivered through the Dassault Medidata Platform and its Clinical Trial Management capabilities.
|
 |
Moderna | Life Sciences | 5600 | $6.8B | United States | Dassault Systemes | Dassault Medidata Platform | Clinical Trial Management | 2015 | n/a |
In 2015, Moderna implemented the Dassault Medidata Platform for Clinical Trial Management. The Dassault Medidata Platform was used by Moderna to support its COVID-19 vaccine clinical trials and specifically to underpin large-scale Phase 3 program execution.
The implementation centered on Medidata Rave EDC, Medidata eCOA, and Medidata Detect, with Rave EDC providing centralized electronic data capture, eCOA enabling patient reported outcomes and electronic clinical outcome assessments, and Detect supporting remote and site monitoring capabilities. Configuration focused on patient-centric data collection workflows and virtualized capture, aligning eCOA instruments and EDC case report forms to a distributed enrollment and follow up process.
Operational coverage included remote and virtualized data capture across the United States and in global trial sites, enabling decentralized trial activities and distributed patient engagement. The program impacted clinical operations, data management, site monitoring, and patient engagement functions, and the rollout supported Phase 3 enrollment and trial execution, accelerating enrollment and conduct during the pandemic as reported by Moderna.
|
 |
|
Education | 6500 | $1.3B | United Kingdom | Dassault Systemes | Dassault Medidata Platform | Clinical Trial Management | 2022 | n/a |
|
Buyer Intent: Companies Evaluating Dassault Medidata Platform
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||